BioSpecifics Technologies (BioSpecifics Technologies) Change In Payables And Accrued Expense : $1.48 Mil (TTM As of Sep. 2020)

View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Change In Payables And Accrued Expense?

BioSpecifics Technologies's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2020 was $-2.32 Mil. It means BioSpecifics Technologies's Accounts Payable & Accrued Expense declined by $2.32 Mil from Jun. 2020 to Sep. 2020 .

BioSpecifics Technologies's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2019 was $-0.45 Mil. It means BioSpecifics Technologies's Accounts Payable & Accrued Expense declined by $0.45 Mil from Dec. 2018 to Dec. 2019 .

BioSpecifics Technologies Change In Payables And Accrued Expense Historical Data

The historical data trend for BioSpecifics Technologies's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Change In Payables And Accrued Expense Chart

BioSpecifics Technologies Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.07

0.13

0.20

-0.44

-0.45

BioSpecifics Technologies Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.96	1.43	1.92	0.46	-2.32

BioSpecifics Technologies Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.48 Mil.

BioSpecifics Technologies Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Wilbur Street, Lynbrook, NY, USA, 11563

Website

https://www.biospecifics.com

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Executives

Paul Gitman	director	167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth	director	191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman	director, 10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman	director	43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N.	director	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison	officer: Chief Financial Officer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi	director, officer: Chief Executive Officer	41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell	officer: Principal Financial Officer	C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law	officer: SVP Business Development	23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman	director, 10 percent owner, officer: President	1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman	10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487